estr-5-ene-7,17-dione | 2530-05-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: estr-5-ene-7,17-dione
• 英文别名: 19-Nor-androst-5-en-7,17-dion；(8R,9R,10R,13S,14S)-13-methyl-1,2,3,4,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-7,17-dione
• CAS: 2530-05-4
• 化学式: C₁₈H₂₄O₂
• 分子量: 272.387
• InChiKey: YRRGNZGUKMXMKK-ASJPCPMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3β,19-Diacetoxy-17β-benzoyloxy-androst-5-en 在 chromium(VI) oxide 、 盐酸 、 aluminum oxide 、 sodium chromate(VI) 、 硫酸 、 sodium acetate 、 乙酸酐 、 溶剂黄146 作用下， 以 乙醇 、 丙酮 、 苯 为溶剂， 生成 estr-5-ene-7,17-dione
  参考文献：
  名称：

  Lederer,F.; Ourisson,G., Bulletin de la Societe Chimique de France, 1965, p. 1298 - 1308

  摘要：

  DOI：

文献信息

• Topical treatment for mastalgia
  申请人：——

  公开号：US20040018991A1

  公开（公告）日：2004-01-29

  A composition for medicinal treatment by means of topical administration is described, which contains an aromatase inhibitor, in addition to conventional constituents of topical forms of administration. The active ingredient or the composition containing this active ingredient is especially suitable for the prophylaxis and for the treatment of mastalgia.

  本文描述了一种用于局部给药的医疗治疗组合物，其中包含一种芳香化酶抑制剂，除了传统的局部给药成分之外。这种活性成分或含有该活性成分的组合物特别适用于乳房疼痛的预防和治疗。
• composition and uses for influencing hair growth
  申请人：Schmidt Alfred

  公开号：US20110117218A1

  公开（公告）日：2011-05-19

  The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

  该发明描述了一种组合物，该组合物包括至少一种从化学合成芳香化酶抑制剂和大豆和油菜籽提取物中选择的芳香化酶抑制剂和至少一种植物提取物，该植物提取物含有从植物中提取的一个或多个活性成分，所述活性成分从5α还原酶I型和/或II型抑制剂和雄激素受体阻断剂中选择，该组合物例如包含在一种组合物中，并具有影响头发生长的特殊性质。还描述了该组合物的用途。
• Composition and uses for influencing hair growth
  申请人：S.W. Patentverwertungs Limited

  公开号：US11052059B2

  公开（公告）日：2021-07-06

  The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

  本发明描述了至少一种芳香化酶抑制剂（分别选自化学合成芳香化酶抑制剂和具有芳香化酶抑制作用的大豆和油菜籽萃取物）与至少一种植物萃取物的组合，该植物萃取物含有一种或多种从植物中提取的活性成分物质，这些活性成分物质选自 5α 还原酶 I 型和/或 II 型抑制剂以及雄激素受体阻断剂。此外，还介绍了这种组合物的用途。
• Aromatase marking
  申请人：——

  公开号：US20040241087A1

  公开（公告）日：2004-12-02

  Compounds are described which exhibit an inhibitory action towards the enzyme aromatase and which comprise at least one detectable group. Such compounds are excellently suitable for medical diagnosis and/or for therapy, particularly for tumor diseases and above all for breast cancer.

  所述化合物对芳香化酶具有抑制作用，并包含至少一个可检测基团。这些化合物非常适合医学诊断和/或治疗，特别是肿瘤疾病，尤其是乳腺癌。
• Synthesis of Androst-5-en-7-ones and Androsta-3,5-dien-7-ones and Their Related 7-Deoxy Analogs as Conformational and Catalytic Probes for the Active Site of Aromatase
  作者：Mitsuteru Numazawa、Ayako Mutsumi、Mii Tachibana、Kumiko Hoshi

  DOI：10.1021/jm00040a012

  日期：1994.7

  A series of androst-5-en-7-ones and androsta-3,5-dien-7-ones and their 7-deoxy derivatives, respectively, were synthesized and tested for their abilities to inhibit aromatase in human placental microsomes. All the steroids inhibited the enzyme in a competitive manner with K-i's ranging from 0.058 to 45 mu M. The inhibitory activities of 17-oxo compounds were much more potent than those of the corresponding 17 beta-alcohols in each series. Steroids having an oxygen function (hydroxy or carbonyl) at C-19 were less potent inhibitors than the corresponding parent compounds having a 19-methyl group. 3,5-Dien-7-one 24 and its 19-hydroxy and 19-oxo derivatives (12 and 13) as well as 19-oxo-5-en-7-one 3 caused a time-dependent inactivation of aromatase only in the presence of NADPH in which the k(inact) values of 19-als 3 and 13 (0.143 and 0.189 min(-1), respectively) were larger than those of the corresponding 19-methyl (23 and 24) and 19-hydroxy (1 and 12) steroids, respectively. 19-Nor-5-en-7-one 4 but not its 3,5-diene derivative 14 also inactivated the enzyme in a time-dependent manner. In contrast, 7-deoxy steroids 21 and 27, having a 19-methyl group, did not cause it. The inactivations were prevented by the substrate androstenedione, and no significant effects of L-cysteine on the inactivations were observed in each case. The results suggest that oxygenation at C-19 would be at least in part involved in the inactivations caused by the inhibitors 23 and 24. The conjugated enone structures should play a critical role in the inactivation sequences.